Serum peroxisome proliferator-activated receptor-gamma levels in acute phase of male patients with schizophrenia and their relationship with metabolic parameters

References

• Gervois P, Fruchart JC, Staels B. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab. 2007;3(2):145–156. doi: 10.1038/ncpendmet0397
   Google Scholar
• Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 2008;454(7203):470–477. doi: 10.1038/nature07202
   PubMed Web of Science ®Google Scholar
• Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82–86. doi: 10.1038/34184
   PubMed Web of Science ®Google Scholar
• Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79–82. doi: 10.1038/34178
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79(7):1147–1156. doi: 10.1016/0092-8674(94)90006-X
   PubMed Web of Science ®Google Scholar
• Sundararajan S, Gamboa JL, Victor NA, et al. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience. 2005;130(3):685–696. doi: 10.1016/j.neuroscience.2004.10.021
   PubMed Web of Science ®Google Scholar
• Mathur A, Law MH, Hamzehloei T, et al. No association between the PPARG gene and schizophrenia in a British population. Prostaglandins Leukot Essent Fatty Acids. 2009;81(4):273–277. doi: 10.1016/j.plefa.2009.06.001
   Web of Science ®Google Scholar
• Herken H, Erdal M, Aydin N, et al. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol. 2009;28(10):515–519. doi: 10.1089/dna.2009.0893
   Web of Science ®Google Scholar
• Kang SH, Lee JI, Chang AK, et al. Genetic polymorphisms in the HTR2C and peroxisome proliferator-activated receptors are not associated with metabolic syndrome in patients with schizophrenia taking clozapine. Psychiatry Investig. 2011;8(3):262–268. doi: 10.4306/pi.2011.8.3.262
   Web of Science ®Google Scholar
• Yi Z, Fan X, Wang J, et al. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study. Psychiatry Res. 2012;200(2–3):79–82. doi: 10.1016/j.psychres.2012.05.020
   Web of Science ®Google Scholar
• Arulmozhi DK, Dwyer DS, Bodhankar SL. Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice. Life Sci. 2006;79(19):1865–1872. doi: 10.1016/j.lfs.2006.06.016
   PubMed Web of Science ®Google Scholar
• Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997;171:502–508. doi: 10.1192/bjp.171.6.502
   PubMed Web of Science ®Google Scholar
• Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212–217. doi: 10.1192/bjp.177.3.212
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123–1131. doi: 10.1001/archpsyc.64.10.1123
   PubMed Web of Science ®Google Scholar
• Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–1132. doi: 10.1016/j.jacc.2010.05.034
   PubMed Web of Science ®Google Scholar
• Emul M, Kalelioglu T. Etiology of cardiovascular disease in patients with schizophrenia: current perspectives. Neuropsychiatr Dis Treat. 2015;11:2493–2503. doi: 10.2147/NDT.S50006
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Vancampfort D, De Herdt A, et al. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39(2):295–305. doi: 10.1093/schbul/sbs082
   PubMed Web of Science ®Google Scholar
• Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101(1–3):273–286. doi: 10.1016/j.schres.2007.12.487
   PubMed Web of Science ®Google Scholar
• Liu YR, Hu TM, Lan TH, et al. Association of the PPAR-γ gene with altered glucose levels and psychosis profile in schizophrenia patients exposed to antipsychotics. Psychiatry Investig. 2014;11(2):179–185. doi: 10.4306/pi.2014.11.2.179
   Web of Science ®Google Scholar
• Chen CH, Lu ML, Kuo PH, et al. Gender differences in the effects of peroxisome proliferator-activated receptor γ2 gene polymorphisms on metabolic adversity in patients with schizophrenia or schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):239–245. doi: 10.1016/j.pnpbp.2010.11.014
   Web of Science ®Google Scholar
• Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs. 2011;25(12):1035–1059. doi: 10.2165/11596300-000000000-00000
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull. 2013;39(6):1174–1179. doi: 10.1093/schbul/sbt141
   PubMed Web of Science ®Google Scholar
• Feinstein DL. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther. 2003;5(1):67–73. doi: 10.1089/152091503763816481
   Google Scholar
• Martínez-Gras I, Pérez-Nievas BG, García-Bueno B, et al. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr Res. 2011;128(1–3):15–22. doi: 10.1016/j.schres.2011.01.018
   PubMed Web of Science ®Google Scholar